These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. Lee YP; Jung HA; Lee MS; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI; Lee SH J Neurooncol; 2022 Feb; 156(3):541-549. PubMed ID: 35094201 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
7. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799 [TBL] [Abstract][Full Text] [Related]
9. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Bokstein F; Shpigel S; Blumenthal DT Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689 [TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. Zhang G; Huang S; Wang Z J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132 [TBL] [Abstract][Full Text] [Related]
15. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Omuro AM; Delattre JY Curr Opin Neurol; 2008 Dec; 21(6):717-9. PubMed ID: 18989118 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Artene SA; Turcu-Stiolica A; Hartley R; Ciurea ME; Daianu O; Brindusa C; Alexandru O; Tataranu LG; Purcaru SO; Dricu A Onco Targets Ther; 2016; 9():6669-6677. PubMed ID: 27877052 [TBL] [Abstract][Full Text] [Related]
18. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892 [TBL] [Abstract][Full Text] [Related]
19. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Guiu S; Taillibert S; Chinot O; Taillandier L; Honnorat J; Dietrich PY; Maire JP; Guillamo JS; Guiu B; Catry-Thomas I; Capelle F; Thiebaut A; Cartalat-Carel S; Deville C; Fumoleau P; Desjardins A; Xuan KH; Chauffert B Rev Neurol (Paris); 2008; 164(6-7):588-94. PubMed ID: 18565358 [TBL] [Abstract][Full Text] [Related]